You are seeing these quotes based on previous browsing related to sectors such as
| Latest | Forecast | |
|---|---|---|
| Div Yield | 0.0% | 0.0% |
| Div Cover | n/a | n/a |
| Op Mrgn | -5,694.3% | 0.0% |
| ROCE | 0.0% |
| Latest | Forecast | |
|---|---|---|
| P/E | -1.8 | 0.0 |
| PEG | 0.0 | -999,999.0 |
| Price / Revenue | 135.7 | 4.4 |
| Price / Book value | 2.6 |
| Latest | Forecast | |
|---|---|---|
| Revenue | 152.4% | 0.0% |
| PBT | 0.0% | n/a |
| EPS | 0.0% | 0.0% |
| DPS | n/a | 0.0% |
| Year Ending | Revenue (£m) |
Pre-tax (£m) |
EPS | P/E | PEG | EPS Growth | Div | Yield |
|---|---|---|---|---|---|---|---|---|
| 2017-12-31 | n/a | -23.99 | -26.08p | -12.8 | 0.0 | n/a | n/a | 0.0% |
| 2018-12-31 | n/a | -28.44 | -36.17p | -2.9 | 0.0 | n/a | n/a | 0.0% |
| 2019-12-31 | 0.21 | -29.43 | -36.75p | -2.7 | 0.0 | n/a | n/a | 0.0% |
| 2020-12-31 | 0.53 | -30.35 | -22.80p | -5.7 | 0.0 | n/a | n/a | 0.0% |
| More positive data reported from 4D Pharma trial of 'Blautix' Sharecast News | 24 May |
|---|---|
| 4D Pharma taps John Beck as its new finance chief Sharecast News | 01 Mar |
| 4D Pharma inks collaboration with Merck and Pfizer Sharecast News | 08 Feb |
| Holding(s) in Company | 06-Jan-22 10:07 |
|---|---|
| Participation in Upcoming Investor Conference | 05-Jan-22 07:00 |
| 4D pharma appoints John Doyle as CFO | 04-Jan-22 07:00 |
| Grant of Options | 04-Jan-22 07:00 |
| 4D pharma Phase 1/2 asthma study Part A results | 13-Dec-21 07:00 |